Edition:
India

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

85.19USD
2:29am IST
Change (% chg)

$4.51 (+5.59%)
Prev Close
$80.68
Open
$81.82
Day's High
$85.55
Day's Low
$80.43
Volume
424,490
Avg. Vol
351,416
52-wk High
$85.55
52-wk Low
$38.43

Chart for

About

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-re... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $5,508.56
Shares Outstanding(Mil.): 88.22
Dividend: --
Yield (%): --

Financials

BRIEF-Neurocrine Biosciences Presents Long-Term Data Analyses From Open-Label Kinect 4 Phase III Study

* NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

05 Dec 2017

BRIEF-Neurocrine Biosciences appoints Matt Abernethy as CFO

* Neurocrine Biosciences appoints Matt Abernethy as chief financial officer

21 Nov 2017

BRIEF-Neurocrine Biosciences reports Q3 loss per share $0.13

* Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S

02 Nov 2017

BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza

* Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome

26 Oct 2017

BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine

* Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza

* Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)

05 Oct 2017

BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences

* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​ Source: (http://bit.ly/2wOUVQY) Further company coverage:

08 Sep 2017

BRIEF-Neurocrine Biosciences Q2 loss per share $0.68

* Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S

04 Aug 2017

Earnings vs. Estimates